The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis

Overview

Journal Nutrients

Date 2024 Jul 13

PMID 38999862

Authors

Youhe Wu

Yuetong Li

Qi Zheng

Lanjuan Li

Affiliations

Soon will be listed here.

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with gut microbiota imbalance playing a significant role. There are increasing numbers of research studies exploring treatment options involving probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT), but it is still uncertain which treatment option is superior. The research was conducted on various databases and unpublished trial data (up to February 2023). Randomized controlled trials (RCTs) were screened for adult patients with IBS comparing interventions with placebo. Probiotics, prebiotics, synbiotics, and FMT were assessed for their impact using mean difference and Bayesian network meta-analysis. Out of 6528 articles, 54 were included for probiotics, 7 for prebiotics/synbiotics, and 6 for FMT. Probiotics showed improvement in IBS symptoms, particularly with and strains. Prebiotics and synbiotics did not show significant improvement. Network meta-analysis indicated the favorable effects of probiotics (OR = 0.53, 95% CI, 0.48 to 0.59) and FMT (OR = 0.46, 95% CI, 0.33 to 0.64) on IBS, with no serious adverse events reported. In short, probiotics and FMT are effective for managing IBS, with and being dominant strains. However, the most effective probiotic combination or strain remains unclear, while prebiotics and synbiotics did not show significant improvement.

Citing Articles

The role of colonic microbiota amino acid metabolism in gut health regulation.

Chen Y, Fang J Cell Insight. 2025; 4(2):100227.

PMID: 39926315 PMC: 11803165. DOI: 10.1016/j.cellin.2025.100227.

Impact of Microbiota on Irritable Bowel Syndrome Pathogenesis and Management: A Narrative Review.

Almonajjed M, Wardeh M, Atlagh A, Ismaiel A, Popa S, Rusu F Medicina (Kaunas). 2025; 61(1).

PMID: 39859091 PMC: 11766696. DOI: 10.3390/medicina61010109.

Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study.

Gasiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, Padysz M J Clin Med. 2025; 14(1.

PMID: 39797089 PMC: 11720862. DOI: 10.3390/jcm14010006.

Therapeutic potential of in gastrointestinal and hepatic disease.

Duan J, Li Q, Cheng Y, Zhu W, Liu H, Li F MedComm (2020). 2024; 5(12):e70017.

PMID: 39687780 PMC: 11647740. DOI: 10.1002/mco2.70017.

Consumption of resistant potato starch produces changes in gut microbiota that correlate with improvements in abnormal bowel symptoms: a secondary analysis of a clinical trial.

Bush J, Alfa M BMC Nutr. 2024; 10(1):152.

PMID: 39605008 PMC: 11600726. DOI: 10.1186/s40795-024-00962-7.

References

Holvoet T, Joossens M, Vazquez-Castellanos J, Christiaens E, Heyerick L, Boelens J . Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology. 2020; 160(1):145-157.e8. DOI: 10.1053/j.gastro.2020.07.013. View

Ooijevaar R, Terveer E, Verspaget H, Kuijper E, Keller J . Clinical Application and Potential of Fecal Microbiota Transplantation. Annu Rev Med. 2018; 70:335-351. DOI: 10.1146/annurev-med-111717-122956. View

Barbara G, Stanghellini V, Cremon C, De Giorgio R, Corinaldesi R . What is the effect of inflammation on intestinal function?. Inflamm Bowel Dis. 2008; 14 Suppl 2:S140-4. DOI: 10.1002/ibd.20701. View

Rogha M, Esfahani M, Zargarzadeh A . The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench. 2014; 7(3):156-63. PMC: 4129566. View

Roberts L, McCahon D, Holder R, Wilson S, Hobbs F . A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol. 2013; 13:45. PMC: 3605320. DOI: 10.1186/1471-230X-13-45. View

Barraza-Ortiz D, Perez-Lopez N, Medina-Lopez V, Minero-Alfaro J, Zamarripa-Dorsey F, Fernandez-Martinez N . Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study. Dig Dis. 2020; 39(3):294-300. DOI: 10.1159/000510950. View

Whorwell P, Altringer L, Morel J, Bond Y, Charbonneau D, OMahony L . Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006; 101(7):1581-90. DOI: 10.1111/j.1572-0241.2006.00734.x. View

Sinn D, Song J, Kim H, Lee J, Son H, Kyung Chang D . Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008; 53(10):2714-8. DOI: 10.1007/s10620-007-0196-4. View

Andresen V, Gschossmann J, Layer P . Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020; 5(7):658-666. DOI: 10.1016/S2468-1253(20)30056-X. View

10.

Chinn S . A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000; 19(22):3127-31. DOI: 10.1002/1097-0258(20001130)19:22<3127::aid-sim784>3.0.co;2-m. View

11.

Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P . A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2008; 32(2):147-52. DOI: 10.1016/j.gcb.2007.06.001. View

12.

Guglielmetti S, Mora D, Gschwender M, Popp K . Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011; 33(10):1123-32. DOI: 10.1111/j.1365-2036.2011.04633.x. View

13.

Qin H, Cheng C, Tang X, Bian Z . Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014; 20(39):14126-31. PMC: 4202343. DOI: 10.3748/wjg.v20.i39.14126. View

14.

Canakis A, Haroon M, Weber H . Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2019; 27(1):28-35. DOI: 10.1097/MED.0000000000000523. View

15.

Xu L, Yu W, Jiang J, Feng X, Li N . [Efficacy of pectin in the treatment of diarrhea predominant irritable bowel syndrome]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015; 18(3):267-71. View

16.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

17.

Niv E, Halak A, Tiommny E, Yanai H, Strul H, Naftali T . Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab (Lond). 2016; 13:10. PMC: 4744437. DOI: 10.1186/s12986-016-0070-5. View

18.

Pittayanon R, Lau J, Yuan Y, Leontiadis G, Tse F, Surette M . Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019; 157(1):97-108. DOI: 10.1053/j.gastro.2019.03.049. View

19.

Holtmann G, Ford A, Talley N . Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2017; 1(2):133-146. DOI: 10.1016/S2468-1253(16)30023-1. View

20.

Hong K, Kang H, Im J, Ji G, Kim S, Jung H . Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver. 2010; 3(2):101-7. PMC: 2852694. DOI: 10.5009/gnl.2009.3.2.101. View